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ventilation, 2% (group I) vs. 9% (group II), p<0.01; preoperative inotropes,
11% (group I) vs. 37% (group II), p<0.01. Among the donors, age older than
60 years, 7% (group I) vs. 13% (group II), p=0.01, norepinephrine support at
retrieval, 74% (group I) vs. 88% (group II), p<0.01 and ischemic time,
156 min. (group I) vs. 183 min. (group II), p<0.01. Even if the occurrence of
primary graft dysfunction was the similar in both groups, 21% (group I) vs.
27% (group II), this complication was treated with high dose inotropes in 10%
(group I) vs. 2% (group II), p<0.01; with ECMO in 8% (group I) vs. 25%
(group II), p<0.01. One-year mortality and 5-years survival were similar in
both groups: 26% (group I) vs. 29% (group II), 67% (group I) vs. 62%
(group II).
Conclusion: The evolution of waiting list criteria and perioperative use of
ECMO allowed us to transplant sicker recipients, using marginal donors,
without any significant impact on short and mid-term survival.
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Background: Few data are available on the value of BNP in older-old sub-
jects. The aim of this study was to evaluate the benefit of BNP for heart
failure diagnosis in very old patients.
Methods: The BED is a French multicenter observational prospective
study that enrolled 383 very old subjects (≥80 yo) hospitalized in geriatric care
with acute dyspnea. BNP was measured in acute phase, before any diuretic
treatment. Cardiologists categorized the subjects into 3 subgroups according to
ESC criteria and blinded to BNP level: heart failure (HF), respiratory failure
and mixed disease (HF and respiratory failure combined). Subjects with mixed
disease were then reclassified into HF or respiratory failure groups according
to the predominant feature (cardiac or respiratory). We analyzed the prog-
nostic value (sensibility, sensitivity and area under curve (AUC)) of the BNP
for the diagnosis of HF, mixed disease included and excluded.
Results: Mean age was 89±5 years, 66% of the patients were women, 57%
had previous history of HF, 67% hypertension, 13% diabetes, 33% coronary
heart disease and 49% atrial fibrillation. Mean LVEF was 56±13%. Several
patients had non-cardiac comorbidities, malnutrition 48%, severe renal failure
41%, dementia 38%, depression 32%, COPD 17%, and cancer 12%. Fifty per-
cent of the subjects had cardiac dyspnea, 26% respiratory dyspnea and 24%
dyspnea of mixed origin. Mean BNP values were 675 (835), 301 (366), 558
(796) pg/mL (p<0.001) in cardiac dyspnea, respiratory dyspnea and mixed
origin subjects respectively. However, the AUC was only 0.68 and 0.67 with
mixed dyspnea included and excluded respectively. In the overall population,
the sensitivity and specificity was 86% and 33% for a cutoff of 100 pg/mL,
48% and 73% for a cutoff of 400 pg/mL and 26% and 86% for a cutoff of
800 pg/mL. Similar results were obtained with mixed dyspnea subjects excluded.
Conclusion: In very old patients, BNP has a poor sensitivity and speci-
ficity for discriminating cardiac from pulmonary dyspnea.
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Introduction: Heart failure with preserved ejection fraction (HFPEF) is
an incurable but prevalent disease associated with poor prognosis. Whether
cardiac MRI with late enhancement (LE) analysis could provide new
insight into myocardial structure and pathophysiology is investigated in this
work.
Methods: 50 consecutive and clinically stabilized patients with HFPEF
(Framingham clinical criteria, EF >50% and BNP level >100 pg/ml) were
explored by MRI (Siemens 1.5T, Symphony and Avanto) for cine-SSFP as
well as 10-min LE following Gadolinium infusion sequences, 2 months after
an acute decompensation. Patients were stratified according to the distribution
of LE imaging at least in 2 adjacent segments (subendocardial, subepicardial
or intramyocardial). Interestingly subendocardial LE localization was consid-
ered as a marker of myocardial infarction. Demographic data and medical his-
tory were also collected.
Results: Mean age was 73±9 yrs and sex ratio was 0.85. The magnitude of
hypertension, diabetes and chronic kidney disease was 78%, 47% and 24%,
respectively. A history of ischemic heart disease (prior MI and/or isolated cor-
onary lesions) was reported in 23% of pts. By MRI, EF was 57±11%, indexed
left ventricular end-diastolic volume was 78±23 ml/m² and left atrial end-
systolic volume was 111±35 ml. Late enhancement analysis was completed in
47 patients. Twenty two patients had no LE. Among the 25 remaining patients,
subendocardial, intramyocardial and subepicardial LE was found in 62%, 32%
and 20% of cases, respectively. The diagnosis of myocardial infarction was
more frequently detected by MRI than orally reported in the medical report
(32% vs. 23% respectively, p<0,0001) overall.
Conclusion: Cardiac MRI provides new insight into HFPEF by revealing
more silent ischemic heart disease than orally documented
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Background: the prevalence of atrial arrhythmias (AAr) in patients with
heart failure (HF) is high, namely in HF with preserved ejection fraction
(HFpEF). KaRen study is a French and Swedish prospective registry enrolling
patients with an acute HFpEF and reassessing these patients 4-8 weeks later
after conventional HF treatment.
Aim: we sought to define the exact prevalence and the main clinical cor-
relates of AAr diagnosed in the patients included in KaRen.
Method: 535 patients were prospectively recruited and 58.5% had a his-
tory of AAr. Clinical characteristics, co-morbidities, risk factors, left ventric-
ular ejection fraction, blood chemistry and drug treatment were recorded at
baseline and 4-8 weeks later.
Results: The main characteristics at baseline and 4-8 weeks follow-up of
the 313 pts with a history of AAr (AAr+) and of the 220 without AAr (AAr-)
are displayed in the table. Patients with AAr were older (p=0.0004) and tend
to have higher NT-proBNP levels at baseline. There were no significant dif-
ferences for diabetes, Serum creatinin, hemoglobin or left ventricular ejection
fraction. In the 313 patients AAr+, 69% were treated by beta-blockers at the
admission (significantly more than in group AAr-, p=0.0034), 59.7% were
treated with an ACE-inhibitor, 60% got an oral anticoagulant (p<0.0001) at
baseline and 73% at the 4-8week visit.
Conclusion: AAr are extremely prevalent in patient admitted for HFpEF.
Prevalence increases with increasing age and higher blood pressure. It leads to
significantly more prescription of beta-blockers. Interestinglly, NT-proBNP
decreased more in AAr+ patients after treatment.
© Elsevier Masson SAS. All rights reserved.
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Introduction: Calibrated integrated backscatter (CIB), a surrogate for
myocardial fibrosis, is deteriorated in hypertrophic, ischemic cardiomyopathy
or in systolic heart failure (HF). Whether CIB may differentiate patients with
heart failure and preserved ejection fraction (HFPEF) at risk of death or HF
reoccurrence has never been investigated.
Methods: 34 patients admitted for HFPEF (Framingham criteria, EF >50%
and BNP level >100 pg/ml) were imaged by echocardiography 2 months fol-
lowing an acute decompensation. We measured left ventricular function, atrial
dimensions and calibrated Integrated Backscatter (CIB) which was obtained
from parasternal long axis by subtracting pericardial CIB intensity from myo-
cardial CIB intensity of the LV anteroseptal and posterior walls (figure). Mea-
surements of calibrated CIB, expressed in decibels, were performed at QRS
complex onset. The primary endpoint was the occurrence of death or hospital-
ization for HF at 12-month F/U.
Results: 11 patients reached the primary endpoint (3 deaths and 8 hos-
pitalizations for HF). In this group at risk, patients had more chronic
obstructive pulmonary disease (p=0.03) and coronary artery bypass
(p=0.008). Despite similar EF (55,7±7,3 vs. 61,5±10,8 p=0,25), we
observed larger left atrial diameter (49.5 mm±6.6 vs. 44.2 mm±7.0 p=0.05)
and area (28.8±6.2 cm² vs. 24.5±5.1 cm², p=0.044) in patients with endpoint
vs. no endpoint. Patients with clinical endpoint showed more anteroseptal
and posterior wall myocardial ultrasound reflectivity (–12.8 dB±7.4 vs. –22.7 dB±
8.1 p=0.0017 and –14.8±5.7 vs. 21.3+/-8.0 p=0.021) as compared with
event-free patients.
Conclusion: Our data support the hypothesis that calibrated CIB, a surro-
gate for myocardial fibrosis, identifies HFPEF patients at risk of death or HF
hospitalization.
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Introduction: Pulmonary hypertension (PH) is frequent among elderly
patients. The most common causes of PH in this population are severe valve
diseases and heart failure with decreased left ventricular ejection fraction
(LVEF). PH in older patients without valve disease and with preserved LVEF
is less known: the aim of our study was to determine the characteristics of
older patients with PH despite preserved LVEF and normal valves.
Methods: We included prospectively patients over 70 year of age, with PH
suspected during echocardiography and confirmed by pressure measurements
during right heart catheterization. The exclusion criteria were significant valve
disease and LVEF under 50%.
Results: Between November 2010 and November 2011, we included 26
consecutive patients (17 women), 78±5 years old with systolic pulmonary
arterial pressure of 68±15 mm Hg. Nineteen patients (73%) had been hospital-
ized for heart failure previously and 59% were in NYHA III-IV functional
class. The six-minute walk distance was 226±132 m, the mean NT-proBNP
level 1462 pg/ml. Fourteen patients (54%) had atrial fibrillation. Nine patients
Mediane
 [25 – 75th pctl]
AAr+ 
= 313 (58.5%)
AAr-
=220 (41.5%)
p-value
Age 80[73-84] 77[70-84] 0.003
Body Mass Index 28[24-32] 25[25-33] ns
Left ventricular 
ejection fraction
55 [50-60] 55[50-60] ns
Systolic blood 
pressure (mm Hg)
144[125-160] 151[132-180] 0.0002
NT-proBNP 
admission
2654 [1356-4921] 2113 [1040-4630] 0.06
NT-proBNP 4-8 
weeks
1710 [819- 2800] 2113 [1040- 1948] <0.001
Figure (abstract 067) – Integrated backscatter measurement
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